Diagnostic Testing & Technology Report

So far, it’s been a good year for Chembio (Medford, NY): The diagnostics company received approval letters from the FDA for pre-market applications (PMAs) for its two rapid HIV test products, Sure Check HIV 1/2 and HIV 1/2 Stat-Pak; introduced Dual Path, a new platform that it will use to create new rapid tests; and saw revenues for the first half of the year rise by 75% compared to the same period in 2005. Next on the company’s to-do list: obtain CLIA waivers for the rapid HIV tests and release PrimaTB Stat-Pak, a rapid test for tuberculosis.